Inventing the COVID vax pill: a matter of convenience and durability

Recent data from Vaxart’s phase 1 trial of its COVID-19 inoculation pill shows potential.

By Kelly Bilodeau • Aug. 17, 2022

The CEO in the ophthalmologist’s coat

In balancing two roles — Lexitas CEO and practicing physician — George Magrath brings a patient-first perspective to developing and advancing eye treatments.

By Alexandra Pecci • Aug. 16, 2022

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

Right under our noses: Could COVID-19 vaccines be better as nasal spray?

Nasal vaccines under development by Codagenix, Xanadu Bio and others have the potential to finally help reduce virus transmission and breakthrough infections.

By Kelly Bilodeau • Aug. 16, 2022

Turning harp seal contraceptives into a ‘new genre’ of cancer treatments

With Andrew Hall at its helm, IMV has evolved an animal contraceptive into a unique drug delivery platform aimed at creating targeted cancer immunotherapies for humans.

By Alexandra Pecci • Aug. 9, 2022

How real world evidence is impacting rare disease drug development

ICON’s Will Maier shares how a more patient-focused approach to trials is leading to alternatives for randomization.

By Kim Ribbink • Aug. 9, 2022

The ‘alarming’ spread of Monkeypox — by the numbers

With vaccine and treatment supplies constrained, the virus is becoming ‘less predictable.’

By Meagan Parrish • Aug. 8, 2022

Editas, Real Chemistry and Compass blaze new trails with pivotal C-suite hires

How these latest executive personnel changes are impacting the industry. 

By Karissa Waddick • Aug. 3, 2022

‘Death by 1,000 cuts:’ How emerging tech could change the journey for ALS patients

EverythingALS aims to speed drug development through improved diagnostics.

By Kelly Bilodeau • Aug. 2, 2022

Taking probiotics where they’ve never gone before

How Seed Health is transforming the microbiome therapeutic market with its pharma-focused drug development approach.

By Karissa Waddick • Aug. 2, 2022

How a speech analysis tool could transform diagnosis and research for Alzheimer’s and beyond

WinterLight’s machine learning platform assesses speech to more accurately identify neurodegenerative diseases.

By Kim Ribbink • Aug. 1, 2022

Personalized data could bring PhysIQ to the forefront of clinical trial evolution

The digital medicine company’s chief strategy officer, John Varaklis, explains how its analytic predictive platform could lead to safer and quicker clinical trials.

By Karissa Waddick • July 28, 2022

What’s next for Biogen? Here’s what executives are saying

A trickling launch for Aduhelm and a middling earnings report give Biogen executives a lot to talk about. Is there hope?

By Michael Gibney • July 27, 2022

Woman of the Week: Applied BioMath's Katie Williams

The 2022 president of Women in Bio is equal parts math and gender parity evangelist. 

By Taren Grom • July 27, 2022

Lupus discovery lends clues to the fight against long COVID

So far, pharma has yet to provide an answer for long COVID. But award-winning lupus research by Yale professor Akiko Iwasaki could help lead the way.

By Kelly Bilodeau • July 27, 2022

Behind Pfizer's new quest to target a 'transformation' in pharma

A combined venture with Roivant — called Priovant Therapeutics — is looking to be a forerunner in the burgeoning autoimmune disease market.

By Kelly Bilodeau • July 25, 2022

A 'total waste'? Drug developers worry if two decades of Alzheimer's research were pointed at the wrong targets

The latest trial failures in Alzheimer's have shown cracks in the foundation of ingrained theories like amyloid plaque clearance. What will it take to move forward?

By Michael Gibney • July 25, 2022

The earlier the better: New consortium leverages infant screening to accelerate treatment

Inozyme Pharma has joined a genomic sequencing program developing a novel rapid test for 388 genetic diseases.

By Kim Ribbink • July 25, 2022

Moderna's next vax target? A little-known cause of birth defects

How the mRNA-based biotech is developing the first-ever prophylactic for a devastating virus.

By Karissa Waddick • July 21, 2022

Woman of the Week: Vaxxinity's Mei Mei Hu

Mei Mei Hu is looking to lead a third biologic ‘revolution’ by developing vaccines for chronic diseases.

By Taren Grom • July 20, 2022

By the numbers: The rising danger of superbugs

A look at how the COVID-19 pandemic exacerbated one of the world’s greatest public health concerns.

By Karissa Waddick • July 20, 2022

Pfizer's former R&D head takes on drug pricing misconceptions in new book

John LaMattina has something to say about the industry — and he hopes patients are listening.

By Meagan Parrish • July 19, 2022

Biotech R&D spending has skyrocketed, and so have opportunities for savings

With R&D costs on the rise, biotechs are embracing new strategies and technologies to make spending more efficient.

By Michael Gibney • July 19, 2022

Making moves: Agios, BeiGene, Biocom California and more announce new key hires

The latest executive personnel changes from around the industry.

By Karissa Waddick • July 18, 2022

Anjarium Biosciences’ CEO on its next-gen gene therapies

Stephen Yoo aims to build on the buzz around the company’s leading-edge gene therapy tech.

By Kim Ribbink • July 15, 2022

Alkermes looks to fill cancer treatment gaps with new immune pathways

The company’s chief medical officer discusses its lead candidate and how it fits into wider oncology trends.

By Kelly Bilodeau • July 14, 2022